Skip to main content

SYSTEMATIC REVIEW article

Front. Nutr.
Sec. Nutrition and Microbes
Volume 11 - 2024 | doi: 10.3389/fnut.2024.1502151
This article is part of the Research Topic Xenobiotics, Gut Microbiota, and Chronic Disease View all 6 articles

Small Intestinal Bacterial Overgrowth And Metabolic Dysfunction-Associated Steatotic Liver Disease

Provisionally accepted
Ziteng Wang Ziteng Wang 1Wentao Tan Wentao Tan 2Jiali Huang Jiali Huang 2Qian Li Qian Li 2Jing Wang Jing Wang 2Hui Su Hui Su 2Chunmei Guo Chunmei Guo 2Hong Liu Hong Liu 2*
  • 1 Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
  • 2 Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Small intestinal bacterial overgrowth (SIBO), characterized by alterations in both the type and quantity of bacteria in the small intestine, leads to impaired intestinal digestion and absorption that can cause a range of clinical symptoms. Recent studies have identified significant changes in the composition of the small intestinal microbiota and metabolomic profiles of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This study systematically reviewed and synthesized the available data to explore the association between SIBO and MASLD. Comprehensive literature searches of the Embase, PubMed, Web of Science, Ovid, and Cochrane databases were conducted. Article quality screening was performed using the Newcastle-Ottawa Quality Assessment Scale. Cross-sectional, cohort, and case-control studies were included. A total of 7200 articles were initially screened, of which 14 were ultimately included for analysis. Individuals with SIBO in both the MASLD and non-MASLD groups were extracted and a chi-square test was performed to calculate the odds ratio (OR) and 95% confidence interval (CI). The I 2 index was used to measure heterogeneity. For heterogeneity >50%, a random effects model was used. There was a clear association between SIBO and MASLD (OR = 3.09; 95% CI 2.09-4.59, I 2 = 66%, p <0.0001).Subgroup analyses by MASLD stage showed that the probability of SIBO positivity increased with MASLD lesion severity. After stratifying by the diagnostic methods for SIBO and MASLD, the meta-analysis results suggest a reduction in inter-group heterogeneity. For the MASLD subgroup diagnosed via liver biopsy, the OR was 4.89. A subgroup analysis of four studies that included intestinal permeability testing revealed an OR of 3.86 (95% CI: 1.80-8.28, I² = 9%, p = 0.0005). A meta-regression analyses revealed that both race and regional development level significantly influenced the relationship between SIBO and MASLD (p = 0.010, p = 0.047). In conclusion, this meta-analyses provides strong evidence that SIBO may contribute to the development and progression of MASLD. The strongest associations were observed between lactulose breath testing,

    Keywords: metabolic dysfunction associated steatotic liver disease, Metabolic associated fatty liver disease, small intestinal bacteria, Breath test, Hydrogen methane breath test

    Received: 26 Sep 2024; Accepted: 03 Dec 2024.

    Copyright: © 2024 Wang, Tan, Huang, Li, Wang, Su, Guo and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hong Liu, Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.